Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001)
Sven Schippling, Jeffrey A. Cohen, Alasdair Coles, D. A. S. Compston, Edward Fox, Massimo Filippi, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Frederik Barkhof, David Margolin, Karthinathan Thangavelu, Douglas L. Arnold (2016). Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001). , 86(16_supplement), DOI: https://doi.org/10.1212/wnl.86.16_supplement.s51.001.
Article18 days agoALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS
Alasdair Coles, Douglas L. Arnold, Frederik Barkhof, Massimo Filippi, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, Karthinathan Thangavelu, Sven Schippling (2016). ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. , 87(12), DOI: https://doi.org/10.1136/jnnp-2016-315106.125.
Article18 days ago